Overview
- Summarizes all the important aspects of CRLs
- Provides potential strategies for targeting various human diseases
- Written by pioneers in the field of ubiquitin and neddylation
Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 1217)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (21 chapters)
-
Front Matter
Keywords
About this book
Editors and Affiliations
About the editors
Dr. Yi Sun completed his medical training in China in the early 1980s, his Ph.D. at the University of Iowa, USA, in 1989, and his postdoctorate at the NCI. Currently, he is a Lawrence-Krause Research Professor of Radiation Oncology, and Director of the Division of Radiation & Cancer Biology, Department of Radiation Oncology at the University of Michigan. His main research aims are validating SAG-Cullin RING Ligase (CRL) and neddylation as cancer targets, and identifying small molecule inhibitors against these targets for anticancer therapy. Dr. Sun is the author of 222 peer- reviewed articles published in various prestigious journals, including Dev Cell, eLife, J Cell Biol, J Clin Invest,Mol Cell,Nature Communications, PNAS, and Cancer Res. He serves as editorial board member of several scientific journals. He was elected as a fellow of the AAAS (American Association for the Advancement of Science) in 2012.
Dr. Wenyi Wei received his B.A. degree from Shandong University in 1993 and pursued his M.S. at the Chinese Academy of Science from 1993 to 1996. Afterwards, Dr. Wei completed his Ph.D. at the MCB department at Brown University and his postdoctorate at the laboratory of Dr. William Kaelin, Jr. at DFCI, Harvard Medical School. In 2006, Dr. Wei moved to the Department Pathology at Beth Israel Deaconess Medical Center, Harvard Medical School, where his research focuses on understanding how aberrant cell signaling events contribute to cell cycle dysregulation and subsequent tumorigenesis, to provide the molecular basis and the rationale to develop novel anti-cancer therapies targeting specific cell signaling pathways.
Dr. Jianping Jin completed his PhD at Texas A&M University at College Station in 2000, and his postdoctorate in Dr. J Wade Harper’s Laboratory at Baylor College of Medicine and then at Harvard Medical School. Currently, he is a Professor and senior investigatorat the Life Science Institute, Zhejiang University, China. His main research projects focus on the ubiquitin signaling pathway, and its roles in cancer and inflammation. He discovered Uba6, the second ubiquitin E1 gene (humans only have two ubiquitin E1 genes), and its specific E2 gene, Use1 (also called Ube2Z). He was among the first to identify the family of DCAF genes, which are substarte adaptors of the Cullin4 ubiquitin ligases. Dr. Jin has published more than 50 peer-reviewed articles, and serves as an editorial member of the Journal of Biological Chemistry. He was a co-organizer for three Cold Spring Harbor Asia meetings on the ubiquitin family.
Bibliographic Information
Book Title: Cullin-RING Ligases and Protein Neddylation
Book Subtitle: Biology and Therapeutics
Editors: Yi Sun, Wenyi Wei, Jianping Jin
Series Title: Advances in Experimental Medicine and Biology
DOI: https://doi.org/10.1007/978-981-15-1025-0
Publisher: Springer Singapore
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2020
Hardcover ISBN: 978-981-15-1024-3Published: 03 January 2020
Softcover ISBN: 978-981-15-1027-4Published: 03 January 2021
eBook ISBN: 978-981-15-1025-0Published: 02 January 2020
Series ISSN: 0065-2598
Series E-ISSN: 2214-8019
Edition Number: 1
Number of Pages: VIII, 372
Number of Illustrations: 51 b/w illustrations, 68 illustrations in colour
Topics: Molecular Medicine, Posttranslational Modification, Cell Biology